The results of a clinical trial presented at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden evaluating Jakafi (ruxolitinib) in individuals with myelofibrosis (MF) reported that treatment can reduce spleen size and it associated symptoms.1,2,3
Individuals with MF and polycythemia vera (PV) may experience pain or fullness under their ribs on the left side of their body. This may occur because of enlargement of their spleen. The spleen is an organ that helps the body fight infection and filter unwanted material, such as old or damaged blood cells. The increased number of blood cells caused by MF may make the spleen work harder causing the spleen to get bigger, a condition referred to as splenomegaly.
Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. Food and Drug Administration for treatment of people with PV who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis, including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
- Guglielmelli, et al. Safety and Efficacy of Ruxolitinib (Rux) in Patients (Pts) with Dipss Low-Risk Myelofibrosis (MF) in the Phase 3b Expanded-Access Jump Study. EHA 2018. Abstract PF623.
- Gupta, et al. Predictors of Response to Ruxolitinib (Rux) in Patients (Pts) with Myelofibrosis (MF) in the Phase 3b Expanded-Access Jump Study. EHA 2018. Abstract PF616.
- Vannucchi, et al. Results from 48-week follow-up of the EXPAND study: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts (50-99 × 109/L) at baseline. EHA 2018. Abstract PF611.
Copyright © 2018 CancerConnect. All Rights Reserved.